Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Public ClinicalTrials.gov record NCT01164501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy and safety of the BI 10773 in type 2 diabetic patients with renal impairment in order to provide these data for approval for BI 10773 as an antidiabetic agent by regulatory authorities.
Study identification
- NCT ID
- NCT01164501
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 741 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- Jul 2012 (Actual)
- Completion
- Jul 2012 (Actual)
- Last update posted
- Jun 16, 2014
2010 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.36.10014 Boehringer Ingelheim Investigational Site | Anaheim | California | — | — |
| 1245.36.10019 Boehringer Ingelheim Investigational Site | Lomita | California | — | — |
| 1245.36.10017 Boehringer Ingelheim Investigational Site | Plantation | Florida | — | — |
| 1245.36.10009 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 1245.36.10018 Boehringer Ingelheim Investigational Site | Honolulu | Hawaii | — | — |
| 1245.36.10015 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1245.36.10021 Boehringer Ingelheim Investigational Site | Endwell | New York | — | — |
| 1245.36.10008 Boehringer Ingelheim Investigational Site | Greenville | North Carolina | — | — |
| 1245.36.10005 Boehringer Ingelheim Investigational Site | Bethlehem | Pennsylvania | — | — |
| 1245.36.10003 Boehringer Ingelheim Investigational Site | Melrose Park | Pennsylvania | — | — |
| 1245.36.10004 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1245.36.10012 Boehringer Ingelheim Investigational Site | Corpus Christi | Texas | — | — |
| 1245.36.10013 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.36.10002 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.36.10007 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1245.36.10023 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 1245.36.10011 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1245.36.10006 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01164501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01164501 live on ClinicalTrials.gov.